Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Deepa S, Subramaniam"'
Autor:
Mario Sznol, Michael Yellin, Tibor Keler, Jose Lutzky, Amy Weise, Margaret K Callahan, Osama Rahma, Rachel E Sanborn, Alexander Starodub, Deepa S Subramaniam, Antonio Jimeno, Tracey Rawls, David A Reardon, Daniel C Cho, Rhonda L Bitting, Michael J Pishvaian, Branimir I Sikic, Naiyer A Rizvi, Julie E Bauman, Thomas Kaley, Fabio Iwamoto, Joachim M Baehring, Jeanny B Aragon-Ching, Thomas R Hawthorne
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Background Phase 1/2 dose-escalation and expansion study evaluating varlilumab, a fully human agonist anti-CD27 mAb, with nivolumab in anti-PD-1/L1 naïve, refractory solid tumors.Methods Phase 1 evaluated the safety of varlilumab (0.1–10 mg/kg) wi
Externí odkaz:
https://doaj.org/article/64a076a7b8714d66afa98dfcc1b8a9bc
Autor:
Chul Kim, Stephen V. Liu, Jennifer Crawford, Tisdrey Torres, Vincent Chen, Jillian Thompson, Ming Tan, Giuseppe Esposito, Deepa S. Subramaniam, Giuseppe Giaccone
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundOsimertinib is an effective first-line therapy option for EGFR-mutant NSCLC, but virtually all patients develop resistance. CRIPTO, through Src activation, has been implicated in resistance to EGFR tyrosine kinase inhibitor (EGFR-TKI) thera
Externí odkaz:
https://doaj.org/article/9e4a8042f8624faea5878ab1f95c2486
Autor:
Giuseppe Esposito, Giuseppe Giaccone, Chul Kim, Stephen V Liu, Deepa S Subramaniam, Tisdrey Torres, Massimo Loda
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Lutathera is a 177Lutetium-labeled somatostatin analog approved for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). Somatostatin receptors are expressed in small cell lung cancer (SCLC). Nivolumab, an anti-PD-1 antibo
Externí odkaz:
https://doaj.org/article/339800a96f024e289659dbef437ef846
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Externí odkaz:
https://doaj.org/article/5286bfb15fc64e648327d1f69ee06dc3
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
Supplementary Materials and Methods, and Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238b4ab5c831dd6063dffdf564c8ad3c
https://doi.org/10.1158/2159-8290.22540037
https://doi.org/10.1158/2159-8290.22540037
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca7eaed273b219faf1bb63ec9cf8694
https://doi.org/10.1158/2159-8290.c.6549263
https://doi.org/10.1158/2159-8290.c.6549263
Autor:
Michael C. Repka, Siyuan Lei, Lloyd Campbell, Simeng Suy, Jean-Marc Voyadzis, Christopher Kalhorn, Kevin McGrail, Walter Jean, Deepa S. Subramaniam, Jonathan W. Lischalk, Sean P. Collins, Brian T. Collins
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Purpose/Objective: High-grade glioma is the most common primary malignant tumor of the CNS, with death often resulting from uncontrollable intracranial disease. Radiation dose may be limited by the tolerance of critical structures, such as the brains
Externí odkaz:
https://doaj.org/article/c70346beeb5045ccb33acb790f35dd54
Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Lung cancer remains a leading cause of mortality with 1.69 million deaths worldwide. Activating mutations in epidermal growth factor receptor (EGFR), predominantly exon 19 deletions and exon 21 L858R mutations, are known oncogenic drivers identified
Externí odkaz:
https://doaj.org/article/f154e7fd5e144db19d2a6ea8c8b45843
Autor:
Deepa S. Subramaniam, Stephen V. Liu, Jeanette Crawford, Jenna Kramer, Jillian Thompson, Hongkun Wang, Giuseppe Giaccone
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
IntroductionSmall cell lung cancer (SCLC) accounts for 15% of all lung cancers and is characterized by high response rates to cytotoxic chemotherapy and equally high rates of relapse. Many resistance mechanisms have been proposed including resistance
Externí odkaz:
https://doaj.org/article/650b427c284843b38bd88dd4de72e43c
Autor:
Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Osama Rahma, Daniel C Cho, Naiyer A Rizvi, Mario Sznol, Jose Lutzky, Julie E Bauman, Rhonda L Bitting, Alexander Starodub, Antonio Jimeno, David A Reardon, Thomas Kaley, Fabio Iwamoto, Joachim M Baehring, Deepa S Subramaniam, Jeanny B Aragon-Ching, Thomas R Hawthorne, Tracey Rawls, Michael Yellin, Tibor Keler
Publikováno v:
Journal for immunotherapy of cancer. 10(8)
BackgroundPhase 1/2 dose-escalation and expansion study evaluating varlilumab, a fully human agonist anti-CD27 mAb, with nivolumab in anti-PD-1/L1 naïve, refractory solid tumors.MethodsPhase 1 evaluated the safety of varlilumab (0.1–10 mg/kg) with